Tegoprubart

Tegoprubart
Monoclonal antibody
Type	?
Clinical data
Other names	AT-1501
Legal status
Legal status	Investigational;
Identifiers
CAS Number	2628092-47-5;
UNII	EK87C62XNH;

Tegoprubart (AT-1501) is an experimental humanized monoclonal antibody that inhibits CD40L. It is developed for ALS^[1] and transplant rejection.^[2]^[3]^[4]^[5]

References

^ Meglio, Marco. "Tegoprubart Demonstrates Safety, Target Engagement of ALS Markers in Phase 2 Study." Neurology Times, 3 Nov. 2022, p. NA. Gale Academic OneFile, link.gale.com/apps/doc/A762611032/AONE?u=anon~b1a7e306&sid=googleScholar&xid=733a3e0e. Accessed 4 Dec. 2023.
^ Gendron, Tania F.; Petrucelli, Leonard (8 November 2023). "Immunological drivers of amyotrophic lateral sclerosis". Science Translational Medicine. 15 (721): eadj9332. doi:10.1126/scitranslmed.adj9332. PMID 37939160. S2CID 265051444.
^ Singh, Avneesh K.; Goerlich, Corbin E.; Zhang, Tianshu; Lewis, Billeta G.T.; Hershfeld, Alena; Mohiuddin, Muhammad M. (July 2023). "CD40-CD40L Blockade: Update on Novel Investigational Therapeutics for Transplantation". Transplantation. 107 (7): 1472–1481. doi:10.1097/TP.0000000000004469. PMC 10287837. PMID 36584382.
^ Anwar, Imran J.; Berman, Dora M.; DeLaura, Isabel; Gao, Qimeng; Willman, Melissa A.; Miller, Allison; Gill, Alan; Gill, Cindy; Perrin, Steve; Ricordi, Camillo; Ruiz, Philip; Song, Mingqing; Ladowski, Joseph M.; Kirk, Allan D.; Kenyon, Norma S. (30 August 2023). "The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates". Science Translational Medicine. 15 (711): eadf6376. doi:10.1126/scitranslmed.adf6376. PMC 10990482. PMID 37647390. S2CID 261340684.
^ Gill, John; Coates, Patrick; Tchervenkov, Jean; Bornstein, Jeffrey; Harden, Paul; Kadatz, Matthew; Witkowski, Piotr (October 2023). "318.5: Emerging data from a study of tegoprubart for the prevention of rejection in kidney transplant recipients: Implications for a similar study in islet cell transplantation". Transplantation. 107 (10S2): 124. doi:10.1097/01.tp.0000994460.57811.03.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Meglio, Marco. "Tegoprubart Demonstrates Safety, Target Engagement of ALS Markers in Phase 2 Study." Neurology Times, 3 Nov. 2022, p. NA. Gale Academic OneFile, link.gale.com/apps/doc/A762611032/AONE?u=anon~b1a7e306&sid=googleScholar&xid=733a3e0e. Accessed 4 Dec. 2023.

[2] Gendron, Tania F.; Petrucelli, Leonard (8 November 2023). "Immunological drivers of amyotrophic lateral sclerosis". Science Translational Medicine. 15 (721): eadj9332. doi:10.1126/scitranslmed.adj9332. PMID 37939160. S2CID 265051444.

[3] Singh, Avneesh K.; Goerlich, Corbin E.; Zhang, Tianshu; Lewis, Billeta G.T.; Hershfeld, Alena; Mohiuddin, Muhammad M. (July 2023). "CD40-CD40L Blockade: Update on Novel Investigational Therapeutics for Transplantation". Transplantation. 107 (7): 1472–1481. doi:10.1097/TP.0000000000004469. PMC 10287837. PMID 36584382.

[4] Anwar, Imran J.; Berman, Dora M.; DeLaura, Isabel; Gao, Qimeng; Willman, Melissa A.; Miller, Allison; Gill, Alan; Gill, Cindy; Perrin, Steve; Ricordi, Camillo; Ruiz, Philip; Song, Mingqing; Ladowski, Joseph M.; Kirk, Allan D.; Kenyon, Norma S. (30 August 2023). "The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates". Science Translational Medicine. 15 (711): eadf6376. doi:10.1126/scitranslmed.adf6376. PMC 10990482. PMID 37647390. S2CID 261340684.

[5] Gill, John; Coates, Patrick; Tchervenkov, Jean; Bornstein, Jeffrey; Harden, Paul; Kadatz, Matthew; Witkowski, Piotr (October 2023). "318.5: Emerging data from a study of tegoprubart for the prevention of rejection in kidney transplant recipients: Implications for a similar study in islet cell transplantation". Transplantation. 107 (10S2): 124. doi:10.1097/01.tp.0000994460.57811.03.

[1]

[2]

[3]

[4]

[5]